Safe and effective: anti‐tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis. Issue 5 (May 2016)

• Record Type: Journal Article
• Authors: Kiely, C. J.; Subramaniam, K.; Platten, J.; Pavli, P.
• Is Part Of: Internal medicine journal. Volume 46:Issue 5(2016)
• Page Start: 616
• Page End: 619
• Publication Date: 2016-05
• Subjects: inflammatory bowel disease -- Crohn disease -- ulcerative colitis -- pregnancy -- tumour necrosis factor‐alpha; Medicine -- Periodicals; 616
• DOI: 10.1111/imj.13057
• Languages: English
• ISSNs: 1444-0903

Abstract

Abstract : Biological therapy, particularly the anti‐tumour necrosis factor (TNF) antibodies, infliximab and adalimumab, are used for the maintenance of remission for patients with inflammatory bowel diseases (IBD). We present 21 pregnancies in IBD patients exposed to anti‐TNF agents between 2007 and 2014. Our study demonstrates that anti‐TNF therapy is safe and effective in pregnancy. Rates of foetal complications are similar to IBD cohorts from the pre anti‐TNF era.